







# Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)

Martin W Hümmert<sup>\*</sup> , Carlotta Stern<sup>\*</sup> , Friedemann Paul, Ankelien Duchow, Judith Bellmann-Strobl, Ilya Ayzenberg, Carolin Schwake, Ingo Kleiter, Kerstin Hellwig , Sven Jarius, Brigitte Wildemann, Makbule Senel, Achim Berthele, Katrin Gighuber, Felix Luessi, Matthias Grothe, Luisa Klotz, Rasmus Schülke, Stefan Gingele, Jürgen H Faiss, Annette Walter, Clemens Warnke , Florian Then Bergh, Orhan Aktas, Marius Ringelstein, Jan-Patrick Stellmann, Vivien Häußler , Joachim Havla , Hannah Pellkofer, Tania Kümpfel, Bruno Kopp<sup>†</sup>, Corinna Trebst<sup>‡</sup>; on behalf of the Neuromyelitis Optica Study Group (NEMOS)<sup>‡</sup>

## Abstract

**Background:** There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).

**Objective:** To assess cognitive performance and changes over time in NMOSD.

**Methods:** This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients. Cognitive functions measured by Symbol Digit Modalities Test (SDMT), Paced Auditory Serial-Addition Task (PASAT), and/or Multiple Sclerosis Inventory Cognition (MuSIC) were standardized against normative data ( $N=157$ ). Intraindividual cognitive performance at 1- and 2-year follow-up was analyzed. Cognitive test scores were correlated with demographic and clinical variables and assessed with a multiple linear regression model.

**Results:** NMOSD patients were impaired in SDMT ( $p=0.007$ ), MuSIC semantic fluency ( $p<0.001$ ), and MuSIC congruent speed ( $p<0.001$ ). No significant cognitive deterioration was found at follow-up. SDMT scores were related to motor and visual disability ( $p_{\text{Bon}}<0.05$ ). No differences were found between aquaporin-4-IgG-seropositive and double-seronegative NMOSD.

**Conclusions:** A subset of NMOSD patients shows impairment in visual processing speed and in semantic fluency regardless of serostatus, without noticeable changes during a 2-year observation period. Neuropsychological measurements should be adapted to physical and visual disabilities.

**Keywords:** Neuromyelitis optica spectrum disorders, neuroimmunology, cognition, cognitive neuropsychology

Date received: 19 September 2022; revised: 27 December 2022; accepted: 30 December 2022

## Introduction

Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory autoimmune diseases of the central nervous system that characteristically affect the optic nerve, spinal cord, or area postrema.<sup>1</sup> In 2008, a study of 30 NMOSD patients reported for the first time negative effects of the diseases on cognition: More than half of the patients performed worse than healthy controls in at least one cognitive score.<sup>2</sup> Subsequent studies showed that NMOSD patients were most

frequently impaired in the domains of attention, information processing speed, and memory.<sup>2–14</sup> The reported prevalence of cognitive impairment in NMOSD varied between 29%<sup>10</sup> and 67% (Table 1).<sup>15</sup>

Previous studies reported heterogeneous results regarding the effect of disease severity on cognitive impairment.<sup>2,3,5,6,8,10,12,15,16</sup> Moreover, studies disagree about the association between depression and cognitive impairment in NMOSD: Correlations between

Multiple Sclerosis Journal

2023, Vol. 29(7) 819–831

DOI: 10.1177/  
13524585231151212

© The Author(s), 2023.



Article reuse guidelines:  
sagepub.com/journals-  
permissions

Correspondence to:

C Trebst

Department of Neurology,  
Hannover Medical School,  
Carl-Neuberg-Str. 1,  
Hannover 30625, Germany.  
trebst.corinna@mh-  
hannover.de

Martin W Hümmert

Carlotta Stern

Stefan Gingele

Bruno Kopp

Corinna Trebst

Department of Neurology,  
Hannover Medical School,  
Hannover, Germany

Friedemann Paul

NeuroCure Clinical  
Research Center, Charité—  
Universitätsmedizin Berlin,  
Freie Universität Berlin,  
Humboldt-Universität zu  
Berlin, Berlin Institute of  
Health, and Max Delbrück  
Center for Molecular  
Medicine, Berlin, Germany/  
Experimental and Clinical  
Research Center, Charité—  
Universitätsmedizin Berlin,  
Freie Universität Berlin,  
Humboldt-Universität  
zu Berlin, Berlin,  
Germany/ Department  
of Neurology, Charité—  
Universitätsmedizin Berlin,  
Freie Universität Berlin,  
Humboldt-Universität zu  
Berlin, and Berlin Institute  
of Health, Berlin, Germany

Ankelien Duchow

Judith Bellmann-Strobl

NeuroCure Clinical  
Research Center, Charité—  
Universitätsmedizin Berlin,  
Freie Universität Berlin,  
Humboldt-Universität zu  
Berlin, Berlin Institute of  
Health, and Max Delbrück  
Center for Molecular  
Medicine, Berlin, Germany/  
Experimental and Clinical  
Research Center, Charité—

Universitätsmedizin  
Berlin, Freie Universität  
Berlin, Humboldt-  
Universität zu Berlin,  
Berlin, Germany

**Ilya Ayzenberg**  
**Carolin Schwake**  
**Kerstin Hellwig**  
Department of  
Neurology, St. Josef  
Hospital, Ruhr University  
Bochum, Bochum,  
Germany

**Ingo Kleiter**  
Department of  
Neurology, St. Josef  
Hospital, Ruhr  
University Bochum,  
Bochum, Germany/  
Marianne-Strauß-Klinik,  
Behandlungszentrum  
Kempfenhausen für  
Multiple Sklerose  
Kranke, Berg, Germany

**Sven Jarius**  
**Brigitte Wildemann**  
Molecular  
Neuroimmunology  
Group, Department of  
Neurology, University of  
Heidelberg, Heidelberg,  
Germany

**Makbule Senel**  
Department of  
Neurology, University of  
Ulm, Ulm, Germany

**Achim Berthele**  
**Katrin Gighlhuber**  
Department of  
Neurology, School of  
Medicine, Technical  
University Munich,  
Klinikum rechts der Isar,  
Munich, Germany

**Felix Luessi**  
Department of  
Neurology, University  
Medical Center, Johannes  
Gutenberg University of  
Mainz, Mainz, Germany

**Matthias Grothe**  
Department of  
Neurology, University  
Medicine of Greifswald,  
Greifswald, Germany

**Luisa Klotz**  
Department of  
Neurology, University  
of Münster, Münster,  
Germany

**Rasmus Schülke**  
Department of Psychiatry,  
Social Psychiatry and  
Psychotherapy, Hannover  
Medical School,  
Hannover, Germany

**Jürgen H Faiss**  
Department of  
Neurology, Asklepios  
Expert Clinic Teupitz,  
Teupitz, Germany

**Annette Walter**  
Department of  
Neurology, Herford  
Hospital, Herford,  
Germany

**Table 1.** Overview of previous studies about cognitive impairment in patients with NMOSD.

Reference	Country	Sample size (n NMOSD patients)	Serostatus (% AQP4-IgG-seropositive)	Definition cognitive impairment	Cognitive assessment	Cognitive impairment (%)
Blanc et al. <sup>2</sup>	France	30	57	>2 SD in $\geq 1$ test	BRB-N Cross tapping test Go/no-go test WAIS-R symbol digit modalities test CVLT-II CLOX DST-Backward PASAT SDMT BRB-N	57 n.a. 54
He et al. <sup>3</sup>	China	22	n.a.	n.a.	Cross tapping test Go/no-go test WAIS-R symbol digit modalities test	57 57 36 n.a.
Blanc et al. <sup>4</sup>	France	28	43	<5% percentile in $\geq 4$ tests	BRB-N Cross tapping test Go/no-go test WAIS-R symbol digit modalities test	57 57 36 n.a.
Seiji et al. <sup>5</sup>	Japan	14	100	$\leq 5\%$ percentile in $\geq 3$ tests	BRB-N	57
Vanotti et al. <sup>6</sup>	Argentina	14	n.a.	<5% percentile in >2 tests	BRB-N	57
Zhang et al. <sup>16</sup>	China	36	69	$\geq 2$ SD in $\geq 2$ domains	MACFIMS	36
Wang et al. <sup>7</sup>	China	50	64	n.a.	CVLT-II PASAT	n.a.
Liu et al. <sup>8</sup>	China	54	70	$\geq 1.5$ SD in $\geq 2$ domains	Symbol Digit Technique Test WCST	48
Moore et al. <sup>15</sup>	United Kingdom	42	71	$\geq 2$ SD percentile in 1 domain	COWAT MACFIMS (without PASAT) CVLT-II	67
Kim et al. <sup>10</sup>	Korea	82	87	<5% percentile in $\geq 3$ domains	Delis-Kaplan Executive Functioning System phonemic and semantic subtest SDMT WAIS-IV Digit Span subtest COWAT Digit Span test HVLT-R PASAT RCFT SDMT Stroop Color and Word tests SVLT DANA COWAT	29 n.a. 32
Hollinger et al. <sup>17</sup>	United States	23	87	n.a.	Digit Span test	n.a.
Kim et al. <sup>11</sup>	Korea	73	89	<5% percentile in $\geq 3$ domains	HVLT-R RCFT PASAT Stroop Color and Word test SVLT BRB-N MACFIMS	32 n.a.
Cho et al. <sup>12</sup>	Korea	14	93	n.a.	Stroop Color and Word test SVLT BRB-N	n.a.
Chavarro et al. <sup>14</sup>	Germany	29	100	>2 SD in BRB-N Index	MACFIMS BRB-N	3

Note: The table lists key points of the largest and most relevant studies for the reported investigation, for more detailed information see Czarniecka et al.,<sup>18</sup> Eizaguirre et al.,<sup>19</sup> and Oertel et al.<sup>13</sup>  
AQP4-IgG: aquaporin-4-immunoglobulin G; BRB-N: Brief Repeatable Battery of Neuropsychological tests; CLOX: Clock Drawing Task; COWAT: Controlled Oral Word Association Test; CVLT-II: California Verbal Learning Test-Second Edition; DANA: Defense Automated Neurobehavioral Assessment; DST-Backward: Digit Span Test backward; HVLT-R: Hopkins Verbal Learning Test-Revised; MACFIMS: Minimal Assessment of Cognitive Function in Multiple Sclerosis; n.a.: not applicable; NMOSD: neuromyelitis optica spectrum disorders; PASAT: Paced Auditory Serial Addition Test; RCFT: Rey Complex Figure Test; SD: Standard deviation; SDMT: Symbol Digit Modalities Test; SVLT: Seoul Verbal Learning Test; WAIS-R: Wechsler Adult Intelligence Scale-Revised; WAIS-IV: Wechsler Adult Intelligence Scale-Fourth Edition; WCST: Wisconsin Card Sorting Test.

depression severity and overall cognitive impairment, or isolated neuropsychological test scores, were found in various studies.<sup>3,6,10,15</sup> In other studies, however, such correlations were absent.<sup>2,12,17</sup>

A major shortcoming of numerous studies is the lack of consideration of antibody status in the study analysis. To date, no study has found a link between the presence of aquaporin-4-immunoglobulin G (AQP4-IgG) and cognitive impairment, but patient samples were small.<sup>2,4,8,11,15,16</sup>

Inconsistent results might be due to high heterogeneity in terms of demographic and clinical characteristics, cognitive measurement methods, and the definition of cognitive impairment. In most former studies, cognitive impairment was defined as scoring below the fifth percentile in two or more subtests. However, there is no consistent definition of cognitive impairment across the studies (Table 1). In addition, small sample sizes (ranging from 14 to 82 participants) and predominantly single-center studies result in low statistical power (Table 1).<sup>13,18,19</sup>

Cognitive impairment seems to occur independently of disease duration.<sup>2,4,5,8,10–12,15–17</sup> Furthermore, it was shown that cognitive impairment exists even in the limited form of NMOSD (i.e. AQP4-IgG-positivity with isolated optic neuritis or myelitis), suggesting that deficits affect patients from the early disease stage.<sup>5</sup> However, so far, no study has investigated cognitive abilities in NMOSD in a longitudinal study design.

The aim of this study was to investigate cognitive performance in a large sample of NMOSD patients with well-established antibody status in a multicenter study design and to gain initial insight into longitudinal cognitive changes in NMOSD patients.

## Methods

### Study participants

In this prospective, longitudinal, observational study patients (aged 18 years or older) were recruited at 17 German Neuromyelitis Optica Study Group (NEMOS) centers ([www.nemos-net.de](http://www.nemos-net.de)) during a 5-year-period (September 2015–April 2021). Only patients diagnosed with NMOSD according to the International Panel for NMO Diagnosis (IPND) 2015 criteria were included in the study.<sup>1,20</sup> Exclusion criteria were predominance of a disease other than NMOSD and lack of informed consent. Moreover, myelin oligodendrocyte glycoprotein-antibody-associated diseases

(MOG-AD) were excluded. Two follow-up assessments were analyzed at 11 to 16 months (follow-up one) and 23 to 28 months (follow-up two). Follow-up data surveyed at a different time interval were excluded.

The assessment included sociodemographic data, data on disability (assessed using the Expanded Disability Status Scale (EDSS) by trained physicians),<sup>21</sup> depressive symptoms (German version of the revised Beck Depression Inventory, BDI-II),<sup>22</sup> fatigue screening (Fatigue Scale for Motor and Cognitive Functions, FSMC),<sup>23</sup> and data from neuropsychological tests. To assess visual and motor disability the EDSS visual and motor function system score was used. Visual impairment was defined as any visual acuity below 1.0 and therefore an EDSS visual function system above zero. BDI-II scores were interpreted according to the following cutoff values: no depressive symptoms 0–8; minimal depressive symptoms 9–13; mild depressive symptoms 14–19; moderate depressive symptoms 20–28; severe depressive symptoms 29–63.<sup>22</sup> Fatigue was defined as FSMC score  $\geq 43$  for mild fatigue;  $\geq 53$  for moderate fatigue;  $\geq 63$  for severe fatigue.<sup>23</sup>

Well-established cell-based assays were used to test for serum antibodies to AQP4- and MOG-IgG.<sup>24,25</sup>

### Standard protocol approvals, registrations, and patient consents

The study was part of the German Ministry of Education and Research (BMBF)-funded German Competence Network Multiple Sclerosis (KKNMS). The NEMOS cohort/KKNMS Nation<sup>NMO</sup>-Study was approved by the ethics boards of the Hannover Medical School (no. 2009-5220) and other participating centers. All participants provided written informed consent before enrollment.

### Neuropsychological test procedures

For neuropsychological testing, the Paced Auditory Serial-Addition Task (PASAT),<sup>26</sup> Symbol Digit Modalities Test (SDMT),<sup>27</sup> and Multiple Sclerosis Inventory Cognition (MuSIC)<sup>28</sup> were administered to the participants. The PASAT is a neuropsychological measure of processing speed in the auditory modality.<sup>29</sup> SDMT is used to examine processing speed in the visual modality. MuSIC, a short test battery used in German-speaking countries, evaluates immediate recall (recall of two orally presented lists of 10 words), semantic fluency including category switching (naming words from two different semantic categories in

**Clemens Warnke**  
Department of Neurology,  
Faculty of Medicine and  
University Hospital Cologne,  
University of Cologne,  
Cologne, Germany

**Florian Then Bergh**  
Department of Neurology,  
University of Leipzig,  
Leipzig, Germany

**Orhan Aktas**  
Department of Neurology,  
Medical Faculty, Heinrich  
Heine University  
Düsseldorf, Düsseldorf,  
Germany

**Marius Ringelstein**  
Department of Neurology,  
Medical Faculty, Heinrich  
Heine University  
Düsseldorf, Düsseldorf,  
Germany/Department  
of Neurology, Center  
for Neurology and  
Neuropsychiatry, LVR-  
Klinikum, Heinrich Heine  
University Düsseldorf,  
Düsseldorf, Germany

**Jan-Patrick Stellmann**  
Department of  
Neurology and Institute  
of Neuroimmunology  
and Multiple Sclerosis  
(INIMS), University  
Medical Center Hamburg-  
Eppendorf, Hamburg,  
Germany/Aix-Marseille  
Univ, CNRS, CRMBM,  
UMR 7339, Marseille,  
France/APHM, Hôpital de  
la Timone, CEMEREM,  
Marseille, France

**Vivien Häubler**  
Department of  
Neurology and Institute  
of Neuroimmunology  
and Multiple Sclerosis  
(INIMS), University  
Medical Center Hamburg-  
Eppendorf, Hamburg,  
Germany

**Joachim Havla** Institute of  
Clinical Neuroimmunology,  
LMU Hospital, Ludwig-  
Maximilians-Universität  
München, Munich,  
Germany/Data Integration  
for Future Medicine  
Consortium, LMU Hospital,  
Ludwig-Maximilians  
Universität München,  
Munich, Germany

**Hannah Pellkofer Tania  
Kümpfel** Institute of  
Clinical Neuroimmunology,  
LMU Hospital, Ludwig-  
Maximilians-Universität  
München, Munich,  
Germany

\* These authors have  
contributed equally to  
this work and share first  
authorship.

† These authors have  
contributed equally to this  
work and share senior  
authorship.

‡ Affiliated members see  
Supplemental Appendix.

alternating sequence within one minute), visual processing speed (congruent speed) and inhibition score (incongruent speed minus congruent speed) from a modified Stroop task (correctly naming 30 visual presented silhouettes of animals with congruent/incongruent written names, respectively), and delayed recall (recall of the first list of words). The different tests were carried out by trained study staff, and each patient completed these cognitive tests in a separate quiet room.

For each patient, the test scores were  $z$  standardized based on normative data from 241 German-speaking healthy controls for the SDMT and PASAT, and 158 German-speaking healthy controls for the MuSIC.<sup>28,30</sup> The normative data include healthy controls with a range of age from 19 to 60 and 62 years, respectively. Therefore, patients 60 years and older ( $n=60$ ) were excluded for baseline analysis to ensure comparability to the normative data. Among patients under 60 years, 81 patients completed the PASAT, 135 the SDMT, and 76 the MuSIC at baseline assessment. Test performance was considered to be impaired if individual  $z$  scores fell below the fifth percentile of the normative distribution. For baseline analysis, we hypothesized that  $z$  scores from the NMOSD sample significantly differ from the normative average (i.e.  $z=0$ ).

#### Statistical analyses

Statistical analyses were carried out with SPSS Version 27. Descriptive data are presented as medians with interquartile range (IQR) or range. For baseline analysis, a one-sample  $t$  test with the  $z$  standardized test scores and the test value 0 was performed. For follow-up analysis paired  $t$  test for normally distributed variables (follow-up one) and the Wilcoxon–Mann–Whitney test for variables with non-normal distribution (follow-up two) was used. We compared AQP4-IgG-seropositive with double-seronegative NMOSD patients, SDMT and MuSIC congruent speed between patients with and without visual impairment, and patients in an acute disease state (attack within the last 30 days of cognitive assessment) with patients in a chronic disease state using a two-sample  $t$  test. The Welch test and Wilcoxon–Mann–Whitney test were used if the assumptions were not given. Furthermore, we evaluated whether baseline neuropsychological test scores correlated with demographic or clinical parameters. The analyzed variables were age, sex, education, disease duration, EDSS motor and visual functional system scores, BDI-II depressive symptoms, and FSMC scores. Correlations were calculated using Spearman's

$\rho$ . For categorical variables, eta coefficient ( $\eta$ ) was used and tested for significance by one-way ANOVA. A multiple linear regression model was conducted to assess the relationship between the different baseline cognitive test values and demographic (age and education) and clinical parameters (serostatus, disease duration, EDSS, BDI-II, and FSMC score). Before analysis, all continuous variables were verified for normal distribution, and if necessary, logarithmic transformation was applied. Extreme values ( $>3$  SD IQR distance) were excluded. Bootstrapping was performed. Dichotomous variables (i.e. education and antibody status) were dummy-coded. A two-sided  $p$ -value  $< 0.05$  was considered statistically significant. Bonferroni correction was applied for correlation analysis and regression model. Effect sizes were calculated as Cohen's  $d$ . Missing data were addressed by pairwise deletion to use all information observed. Sum scores (i.e. BDI-II, FSMC) were calculated only if all subscores were available. Except for baseline analysis with the  $z$  standardized test scores, all patients with available cognitive data were included.

#### Data availability

Anonymized data not published within this article will be made available on reasonable request from any qualified investigator.

## Results


#### Patient's characteristics

Datasets from 174 AQP4-IgG-seropositive patients and 43 double-seronegative patients with a median disease duration of 6 years were included. Double-seronegative patients were negative for both, AQP4-IgG and MOG-IgG. The selection procedure is illustrated in Figure 1. For the follow-up assessment data from 79 (follow-up one with a range of 11 to 16 months to follow-up) and 52 patients (follow-up two with a range of 23 to 28 months to follow-up) were available. Twenty-four percent ( $n=19/79$ ) and 22% ( $n=11/51$ ) had at least one attack between baseline and follow-up one and follow-up two, respectively. Median BDI-II score was 8 (i.e. no depressive symptoms) and median FSMC score was 56 (i.e. moderate fatigue). Demographic and clinical sample characteristics are shown in Table 2.

#### Baseline analysis

At baseline, we considered only patients younger than 60 years ( $n=157$ ) to ensure strict comparability with normative data. Patients performed worse than the





**Figure 1.** CogniNMO-Study—Selection procedure and cohort characterization stratified by serostatus.

Note: Age and disease duration are shown as median with range in years, female sex is shown as percentage. Patient subgroups were defined based on serostatus. EDSS values of 30 patients were missing. This did not affect the representativeness of the group composition. AQP4-IgG<sup>+</sup> = aquaporin-4 immunoglobulin G antibody-positive patients; Double seronegative = AQP4- and MOG-antibody negative NMOSD patients; EDSS = Expanded Disability Status Scale (score is shown as median with range); IPND = International Panel for Neuromyelitis Optica (NMO) Diagnosis; MOG(AD) = myelin oligodendrocyte glycoprotein antibody (associated disease); NMOSD = neuromyelitis optica spectrum disorders.

average population norm on the SDMT (mean = -0.37, 95% confidence interval (CI) (-0.63, -0.10)), on MuSIC semantic fluency (mean = -0.42, 95% CI (-0.62, -0.22)), and on MuSIC congruent speed (mean = -1.71, 95% CI (-2.36, -1.06)). Patients performed better than the population norm on MuSIC immediate recall list B (mean = 0.28, 95% CI (0.06, 0.51)). The means with 95% CI are provided in Figure 2 and Table 3.

On at least one test score 40% ( $n = 62/157$ ) of NMOSD patients performed below the fifth percentile. Among patients who completed two or more tests, 19% ( $n = 23/123$ ) showed evidence of impairment on at least two cognitive test scores (Table 4). The highest proportion of impairment in cognitive tests was reached for MuSIC congruent speed ( $n = 31/76$ , 41%).

Twenty-three patients (11 % of all patients), and 15 patients < 60 years (10 % of patients < 60 years) had an attack within the last 30 days of cognitive

assessment. Importantly, there were no significant differences in the cognitive tests between patients in an acute disease state and patients in a chronic disease state (Supplemental eTable 1).

Across all cognitive tests, no significant differences were found between AQP4-IgG-seropositive and double-seronegative NMOSD patients (Supplemental eTable 2). Both groups were comparable in terms of demographic and clinical variables (Supplemental eTable 3).

#### Follow-up analysis

Among all NMOSD patients, there was no significant change in performance across all cognitive test scores at 1- and 2-year follow-up. Regarding MuSIC congruent speed patients performed better at first ( $p = 0.04$ ) and at the second follow-up ( $p = 0.007$ ) compared to baseline. Frequencies of impairment in cognitive tests and mean normative  $z$  scores of cognitive tests at

**Table 2.** Sample characteristics.

	NMOSD all patients ( <i>n</i> =217)		NMOSD patients < 60 years ( <i>n</i> =157)	
	Available <i>n</i>	Median (IQR)	Available <i>n</i>	Median (IQR)
<b>Demographic characteristics</b>				
Age, years	215	52 (39–60)	157	47 (36–53)
Range of age		21 to 81		21 to 59
Sex, m:f	214	39:175	156	28:128
Education, % <sup>a</sup>				
No graduation/secondary school <sup>b</sup>	31	18%	15	12%
Secondary school <sup>c</sup>	67	40%	52	41%
High school <sup>d</sup>	71	42%	61	48%
Not available	48		29	
<b>Clinical characteristics</b>				
Antibody status, AQP4 <sup>+</sup> : double seronegative	217	174:43	157	123:34
Disease duration, years	212	6 (2–12)	154	6 (2–12)
Time interval since last relapse, months	201	21 (57–5)	146	19 (55–5)
<b>EDSS</b>				
baseline	187	3.5 (2–6)	135	3 (2–4)
1. follow-up	66	3.5 (2–5)	51	3 (2–4)
2. follow-up	44	3.5 (2–4)	34	3.5 (2–4)
EDSS motor functional system score	163	2 (0–3)	116	1 (0–3)
EDSS visual functional system score	165	1 (0–2)	118	1 (0–2)
Immunotherapy, % <sup>e</sup>	159	72%	113	72%
Rituximab	88	41%	60	38%
Oral corticosteroids	22	10%	14	9%
Azathioprine	21	10%	17	11%
Tocilizumab	8	4%	8	5%
Mycophenolate mofetil	5	2%	2	1%
Eculizumab	4	2%	4	3%
Intravenous Immunoglobulin	2	<1%	1	<1%
Methotrexate	2	<1%	2	1%
Glatiramer acetate	2	<1%	1	<1%
Teriflunomide	1	<1%	1	<1%
Others	4	2%	3	2%
<b>Psychopathological characteristics</b>				
Depressive symptoms, BDI-II total	130	8 (4–15)	102	8 (5–15)
None, %	67	51%	53	52%
Minimal, %	19	15%	15	15%
Mild, %	27	21%	22	22%
Moderate, %	12	9%	9	9%
Severe, %	5	4%	3	3%
Fatigue, FSMC total	114	56 (35–70)	91	52 (33–71)
None, %	39	34%	33	36%
Mild, %	14	12%	13	14%
Moderate, %	19	17%	11	12%
Severe, %	42	37%	34	37%

Note: AQP4-IgG: aquaporin-4-immunoglobulin G; BDI-II: Beck's Depression Inventory-II; EDSS: Expanded Disability Status Scale; FSMC: Fatigue Scale for Motor and Cognitive Functions; IQR: interquartile range; NMOSD: neuromyelitis optica spectrum disorders.


<sup>a</sup>Classification according to the German school system.

<sup>b</sup>9 years of school attendance.

<sup>c</sup>10 years of school attendance.

<sup>d</sup>12–13 years of school attendance.

<sup>e</sup>19 patients (12% of all patients) and 12 patients < 60 years (8% of patients < 60 years) were treated with one or more immunotherapies.



**Figure 2.** Mean z scores of cognitive tests at baseline.

Note: Patients  $\geq 60$  years were excluded.

CI=confidence interval; PASAT=Paced Auditory Serial-Addition Task; SDMT=Symbol Digit Modalities Test.

**Table 3.** Mean normative z scores of cognitive tests and *t* test at baseline.

Cognitive test	<i>n</i>	<i>M</i> ( <i>SD</i> )	<i>t</i>	<i>df</i>	95%CI		<i>p</i>
					<i>LL</i>	<i>UL</i>	
PASAT	81	-0.21 (1.09)	-1.75	80	-0.45	0.03	0.08
SDMT	135	-0.37 (1.57)	-2.72	134	-0.63	-0.10	0.007**
MuSIC							
Immediate recall (list A)	92	-0.15 (1.44)	-1.00	91	-0.45	0.15	0.32
Immediate recall (list B)	92	0.28 (1.08)	2.51	91	0.06	0.51	0.01*
Semantic fluency	91	-0.42 (0.97)	-4.11	90	-0.62	-0.22	<0.001**
Congruent speed	76	-1.71 (2.84)	-5.26	75	-2.36	-1.06	<0.001**
Incongruent—Congruent Speed	82	-0.08 (1.40)	-0.53	81	-0.39	0.23	0.60
Delayed recall (list A)	87	0.08 (1.20)	0.64	86	-0.17	0.34	0.52

Note: Patients  $\geq 60$  years were excluded.

CI: confidence interval; *LL*: lower limit; MuSIC: Multiple Sclerosis Inventory Cognition; *p*: uncorrected two-sided *p* value; PASAT: Paced Auditory Serial-Addition Task; SDMT: Symbol Digit Modalities Test; *UL*: upper limit.

\**p* < 0.05. \*\**p* < 0.01.

baseline and follow-up are given in Table 4 and Supplemental eTable 4, respectively.

#### Association between cognitive test scores and clinical and demographic variables

SDMT performance correlated with EDSS visual function score ( $r_s = -0.31$ , 95% CI (-0.46, -0.16)) and

with EDSS motor function score ( $r_s = -0.42$ , 95% CI (-0.55, -0.27)). BDI-II score was associated with SDMT and MuSIC congruent speed, but both correlations did not remain significant after Bonferroni correction. FSMC score was related to SDMT test score ( $r_s = -0.35$ , 95% CI (-0.52, -0.15)). There was no substantial difference in the results when correlation analysis excluded data from patients older than 60 years.

**Table 4.** Frequencies of patients with impairment in cognitive tests at baseline, 1- and 2-year follow-up.

Cognitive test	Baseline			Follow-up #1			Follow-up #2		
	<i>n</i> (available)	<i>n</i> (impaired)	%	<i>n</i> (available)	<i>n</i> (impaired)	%	<i>n</i> (available)	<i>n</i> (impaired)	%
Impairment in $\geq 2$ tests	123	23	19	46	2	4	30	2	7
Impairment in $\geq 1$ test	157	62	40	56	9	16	38	6	16
PASAT	81	9	11	33	1	3	24	3	13
SDMT	135	24	18	51	3	6	36	4	11
MuSIC									
Immediate recall (list A)	92	15	16	27	3	11	14	1	7
Immediate recall (list B)	92	4	4	27	0	0	14	1	7
Semantic fluency	91	8	9	27	0	0	14	0	0
Congruent speed	76	31	41	26	6	23	14	1	7
Incongruent—congruent speed	82	9	11	26	1	4	14	0	0
Delayed recall (list A)	87	6	7	27	2	7	14	0	0

Note: Patients < 60 years were included.

MuSIC: Multiple Sclerosis Inventory Cognition; PASAT: Paced Auditory Serial-Addition Task; SDMT: Symbol Digit Modalities Test.

**Table 5.** Spearman's correlation coefficients at baseline.

	PASAT	SDMT	MuSIC					
			Immediate recall (list A)	Immediate recall (list B)	Semantic fluency	Congruent speed	Incongruent—Congruent speed	Delayed recall (list A)
Age	-0.18	-0.44*	-0.17	-0.26*	-0.12	0.23	0.04	-0.26*
Disease duration	0.01	-0.03	0.02	-0.03	-0.13	-0.02	-0.07	0.01
EDSS: visual function	-0.17	-0.31*	-0.20	-0.08	0.02	0.17	-0.11	-0.10
EDSS: motor function	-0.21	-0.42*	-0.12	-0.19	-0.07	0.19	-0.07	-0.20
BDI-II	-0.03	-0.19	-0.09	-0.00	-0.04	0.31	-0.01	-0.04
FSMC	-0.10	-0.35*	-0.10	0.14	-0.08	0.15	0.04	-0.01

Note: Data from baseline assessment, all patients included.

BDI-II: Beck Depression Inventory-II; EDSS: Expanded Disability Status Scale; FSMC: Fatigue Scale for Motor and Cognitive Functions; MuSIC: Multiple Sclerosis Inventory Cognition; PASAT: Paced Auditory Serial-Addition Task; SDMT: Symbol Digit Modalities Test.

\* $p_{\text{Bon}} < 0.05$  (Bonferroni corrected  $p$  value).

Interestingly, disease duration was not associated with cognitive performance. Correlations between test scores and demographic and clinical parameters are shown in Table 5.

The education level correlated with PASAT ( $\eta = 0.30$ ,  $p = 0.03$ ), SDMT ( $\eta = 0.26$ ,  $p = 0.008$ ), MuSIC immediate recall list A ( $\eta = 0.33$ ,  $p = 0.005$ ), MuSIC congruent speed ( $\eta = 0.27$ ,  $p = 0.04$ ), and MuSIC delayed recall ( $\eta = 0.31$ ,  $p = 0.01$ ). Only MuSIC immediate recall list A remained significant after Bonferroni correction ( $p_{\text{Bon}} < 0.05$ ). There was no association between sex and cognitive performance across all cognitive tests (Supplemental eTables 5 and 6).

Results of multiple linear regression showed that clinical and demographic variables explain a

significant amount of the variance in SDMT score ( $R^2 = 0.45$ , adjusted  $R^2 = 0.39$ ,  $p < 0.001$ ) (Supplemental eTable 7). Only age remained as a significant variable after Bonferroni correction (higher age associated with lower cognitive test performance,  $p = 0.02$ ). The model could not explain variance in PASAT score and MuSIC subtest scores (Supplemental eTables 8–14).

Comparing SDMT test scores of visually impaired patients (EDSS visual function system score  $> 0$ ) with those of patients without visual impairment (EDSS visual function system score  $= 0$ ) revealed a significant difference (mean difference  $= 5.71$ , CI 95% (0.83, 10.59)). No difference between these patient groups was observed at MuSIC congruent speed ( $U = 612.50$ ,  $Z = -1.17$ ,  $p = 0.24$ ).



## Discussion

By examining data from 217 NMOSD patients, this study aimed to characterize the frequency and the type of impairment as well as the intra-individual changes in cognitive performance over a two-year period. We further investigated if clinical or demographic parameters are associated with cognitive performance. We made a clear distinction to MOG-IgG-seropositive patients by including only AQP4-IgG-seropositive or double-seronegative patients in the analysis.

Compared to normative data of healthy controls, NMOSD patients showed below-average visual processing speed and semantic fluency. These results are in line with previous studies.<sup>2–11,14,16,17</sup> In contrast to what has been suggested in some studies, however, we found no impairment with regard to immediate and delayed recall of verbal material presented in the auditory modality.<sup>2–5,7,11,16</sup>

We refer to low performance in cognitive tests as ‘impairment in cognitive tests’ rather than as “cognitive impairment” in an attempt to avoid over-interpretation of the data. As an example, poor performance on tests that involve visuomotor abilities may reflect visual, motor, or cognitive impairment, or any conceivable combination of these. Nineteen percent of patients were impaired in at least two cognitive subtests and 40% of patients exhibited impairment in at least one cognitive subtest. Earlier studies reported a prevalence of 29% to 67%, partly reflecting differences in the definition of impairment (i.e. impairment in one or two or more subtests, see Table 1). Our results from a large prospective multicenter cohort indicate that the prevalence of impairment in cognitive tests in NMOSD seems to be lower than previously assumed. However, previous studies were based on small sample sizes, potentially leading to an overestimation of the true prevalence due to selection bias.

Remarkably, our study reveals that NMOSD patients differed from healthy controls in cognitive performance measured by the SDMT but not by the PASAT. Both tests examine similar cognitive domains (i.e. processing speed) but differ with regard to stimulus modalities (visual vs auditory). Most previous studies reported cognitive impairment measured by the PASAT as well.<sup>2–6,8,9,11,14,16</sup> Nevertheless, our results are in line with two previous studies of larger NMOSD samples.<sup>7,10</sup> Prior findings indicated that SDMT and PASAT test performance were independent of visual impairment.<sup>14</sup> In our study, the SDMT score was moderately to strongly linked to physical and visual disability, unlike PASAT test performance. Other

studies also showed that SDMT test performance can be influenced by visual ability.<sup>31,32</sup> This might be a possible explanation for the discrepancy between SDMT and PASAT results.

As an interim conclusion, our data suggest below-average visual processing speed (as evidenced by the SDMT and MuSIC congruent speed results), but intact auditory processing speed in NMOSD patients. Furthermore, episodic memory for auditory verbal material was preserved in NMOSD patients. The result for MuSIC semantic fluency constituted the sole exception from the rule that visual processing was affected, while nonvisual processing speed was left intact in NMOSD patients. It remains to be seen whether or not this finding reflects the fact that the MuSIC semantic fluency task requires switching between two different semantic categories, i.e., that it places heavy demands on cognitive flexibility.

Results of the correlation analysis indicate that especially the SDMT might not be suitable to assess cognitive abilities in NMOSD patients. EDSS visual and motor function scores along with FSMC scores were significantly related to SDMT test performance even after conservative correction for multiple testing.

No difference in cognitive performance was found between AQP4-IgG-seropositive and double-seronegative patients in direct comparison. A recent study showed that astrocytopathy (as the underlying NMOSD pathology) was not restricted to affected brain areas implying a whole-brain involvement in NMOSD patients. The astrocytic reactions occurred independently of IgG-antibodies against AQP4.<sup>33</sup> This may explain a whole-brain involvement with resulting impairment in visual processing speed and semantic fluency in both, AQP4-IgG-seropositive and double-seronegative NMOSD patients.

No significant cognitive deterioration was observed at 1- and 2-year follow-up. However, retesting effects and/or attrition bias might be responsible for this outcome. In line with other studies, cognitive performance was not linked to disease duration.<sup>2,4,5,8,10–12,15–17</sup>

Considering the rarity of the disease, the strength of this study lies in the large patient sample. In addition, all cognitive tests were performed by experienced and trained study investigators. Furthermore, all clinical data were derived from a cohort database in which, for instance, EDSS data were assessed by trained

physicians. Serological results were crosschecked within the NEMOS network via a central laboratory, allowing valid differentiation between AQP4-IgG-seropositive and double-seronegative NMOSD. Notably, no differences were found.

We examined cognitive functions by well-established neuropsychological tests, but as other studies partly used different test batteries with different subtests, a comparison of the frequency of cognitive deficits across studies is limited and should be made with caution.

Another limitation of our study consists of a potentially too short follow-up interval, possibly explaining why we were unable to detect relevant changes in cognitive performance over time. Furthermore, cognitive deterioration might be masked by learning effects. Indeed, this is emphasized by the fact that patients performed significantly better in most cognitive tests at follow-up. This is a frequently reported phenomenon when testing cognitive performance in longitudinal study designs.<sup>29,34,35</sup> Even though different test versions were used for the PASAT, patients seemed to become familiar with the type of testing. This implies that different stimulus does not prevent practice effects.<sup>34,35</sup> In future studies, a longer observation period should be considered. Another limitation is that data at follow-up are restricted compared to baseline analysis. However, as the neuropsychological testing is part of an ongoing study, some follow-up assessments are still pending.

In the current study, the cognitive performance of NMOSD patients over 60 years of age could not be compared to healthy controls. Thus, normative cognitive data of healthy controls over 60 years should be provided to examine elderly NMOSD patients.

### Conclusion

In summary, this study assessed the extent of impairment in neuropsychological tests in the largest NMOSD sample reported to date and analysed cognition data at follow-up. The data illustrate that NMOSD patients displayed below-average visual processing speed and semantic fluency. The prevalence of impairment in cognitive tests was lower than previously reported. Cognitive performance was independent of disease duration and stayed constant for two years. Furthermore, there was no difference in cognitive performance between AQP4-IgG-seropositive and double-seronegative NMOSD patients. We propose to develop a standard change-sensitive test battery adapted to NMOSD patients for use in future longitu-

dinal studies to examine cognitive performance independently of visual and motor disabilities.

### Acknowledgements

We would like to thank all patients for participating in the study, their family members, and all contributors of the Neuromyelitis Optica Study Group (NEMOS) for their support. Special thanks also go to Sikinika Hache, Karin Fricke, Kathrin Scheiwe, Ilona Cierpka-Leja, Heike Miethke, Monika Höveler, and Carolin Risau for excellent practical support. A sincere thank you to Peter Scherer (Neurozentrum Zehlendorf, Berlin) for providing the raw data on PASAT and SDMT of healthy subjects for comparison in our study.

### Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MWH reports no disclosures relevant to the manuscript. CSt reports no disclosures relevant to the manuscript. FP receives honoraria for lecturing, and travel expenses for attending meetings from Guthy Jackson Foundation, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe, and Celgene. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Teva, Alexion, Roche, Parexel, Viela Bio, and Almirall. FP serves on advisory boards and steering committees for Novartis and Viela Bio and is Associate Editor of Neurology, Neuroimmunology & Neuroinflammation and Academic Editor for *PLoS ONE*. AD reports no disclosures relevant to the manuscript. JBS has received travel grants and speaking honoraria from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi Genzyme, Teva Pharmaceuticals, Roche, and Novartis all unrelated to this work. IA received personal fees from Roche, Alexion, and Merck and received research support from Diamed, none related to this manuscript. CSc reports no disclosures relevant to the manuscript. IK has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Celgene, Hexal, Horizon, Merck, and Roche/Chugai. KH received consultant and speaker honoraria from Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Roche, and Teva. SJ reports no disclosures relevant to the manuscript. BW received grants from the German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, and Klaus Tschira Foundation, grants and personal fees from Merck, Novartis, and

personal fees from Roche; none related to this work. MS has received consulting and/or speaker honoraria from Alexion, Bayer, Biogen, Merck, Roche, and Sanofi Genzyme. She has received research funding from the Hertha-Nathorff-Program. None of this interfered with the current report. AB received speaker and consulting honoraria from Alexion, Biogen, Bayer Healthcare, Celgene, Merck, Novartis Pharma, and Roche; all outside the submitted work. KG reports no disclosures relevant to the manuscript. FL received consultancy fees from Roche and support with travel cost from Teva Pharma. MG received honoraria and travel reimbursements for attending meetings from Biogen, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva and research grants from the German Ministry for Education and Research (BMBF), Merck Serono, and Novartis. None of this interfered with the current report. LK received compensation for serving on Scientific Advisory Boards for Alexion, Biogen, Celgene GmbH, Genzyme, Horizon, Janssen, Merck Serono, Novartis, and Roche. She received speaker honoraria and travel support from Bayer, Biogen, Celgene GmbH, Genzyme, Grifols, Merck Serono, Novartis, Roche, Santhera, and Teva. She receives research support from the German Research Foundation, the IZKF Münster, IMF Münster, Biogen, Immunic AG, Novartis, and Merck Serono. RS reports no disclosures relevant to the manuscript. SG has received speaker honoraria from Alnylam, not related to this manuscript. JHF reports no disclosures relevant to the manuscript. AW received speaker honoraria and meeting expenses from Novartis, Bayer, Biogen, Sanofi Genzyme, Teva, Roche, and Merck. CW has received institutional honoraria and/or grant support from Novartis, Sanofi-Genzyme, Alexion, Janssen, Merck, Biogen, and Roche. FTB has received honoraria for speaking and advisory board consultation from Alexion, Roche, and Horizon Therapeutics; none of these had an impact on this manuscript. OA has received personal fees from Alexion, Bayer Healthcare, Biogen, Celgene, Merck Serono, MedImmune, Novartis, Roche, Teva, and Zambon, outside of the submitted work. MR received speaker honoraria from Novartis, Bayer Vital GmbH, Roche, Alexion, and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Roche, and Merck, none related to this study. JPS reports no disclosures relevant to the manuscript. VH reports no disclosures relevant to the manuscript. JH reports personal fees, research grants and non-financial support from Merck, Novartis, Roche, Santhera, Biogen, Alexion, Celgene, Janssen; and non-financial support of the Guthy-Jackson Charitable Foundation, all outside the submitted work. J.H. is (partially)

funded by the German Federal Ministry of Education and Research [Grant Numbers 01ZZ1603[A-D] and 01ZZ1804[A-H] (DIFUTURE)]. HP received honoraria for lectures from Bayer Health Care, Biogen Idec, and Teva Pharma and travel reimbursement from Novartis. TK has received speaker honoraria and/or personal fees for advisory boards from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma, Alexion, and Biogen as well as grant support from Novartis and Chugai Pharma in the past. None of this interfered with the current report. BK reports no disclosures relevant to the manuscript. CT has received honoraria for consultation and expert testimony from Alexion Pharma Germany GmbH, Biogen Idec/GmbH, Chugai Pharma Germany GmbH, MERCK, Novartis Pharma GmbH and Roche Pharma GmbH. None of this interfered with the current report.


### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The NEMOS cohort/Nation<sup>NMO</sup> is supported by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS; for NEMOS NationNMO-DAB FKZ 01GI1602 C to J.-P.S., NationNMO-PAT FKZ 01GI1602B to O.A., and NationNMO-LAB to B.W.)


### ORCID iDs

Martin W Hümmert  <https://orcid.org/0000-0002-5928-2343>

Carlotta Stern  <https://orcid.org/0000-0002-6150-7564>

Kerstin Hellwig  <https://orcid.org/0000-0003-4467-9011>

Clemens Warnke  <https://orcid.org/0000-0002-3510-9255>

Vivien Häußler  <https://orcid.org/0000-0002-7787-7391>

Joachim Havla  <https://orcid.org/0000-0002-4386-1340>

### Supplemental Material

Supplemental material for this article is available online.

### References

1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 2015; 85: 177–189.

2. Blanc F, Zéphir H, Lebrun C, et al. Cognitive functions in neuromyelitis optica. *Arch Neurol* 2008; 65: 84–88.
3. He D, Chen X, Zhao D, et al. Cognitive function, depression, fatigue, and activities of daily living in patients with neuromyelitis optica after acute relapse. *Int J Neurosci* 2011; 121: 677–683.
4. Blanc F, Noblet V, Jung B, et al. White matter atrophy and cognitive dysfunctions in neuromyelitis optica. *PLoS ONE* 2012; 7: e33878.
5. Saji E, Arakawa M, Yanagawa K, et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. *Ann Neurol* 2013; 73: 65–76.
6. Vanotti S, Cores EV, Eizaguirre B, et al. Cognitive performance of neuromyelitis optica patients: Comparison with multiple sclerosis. *Arq Neuropsiquiatr* 2013; 71: 357–361.
7. Wang Q, Zhang N, Qin W, et al. Gray matter volume reduction is associated with cognitive impairment in neuromyelitis optica. *AJNR Am J Neuroradiol* 2015; 36: 1822–1829.
8. Liu Y, Fu Y, Schoonheim MM, et al. Structural MRI substrates of cognitive impairment in neuromyelitis optica. *Neurology* 2015; 85: 1491–1499.
9. Kim SH, Kwak K, Hyun JW, et al. Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder. *Eur J Neurol* 2016; 23: 1165–1173.
10. Kim SH, Kwak K, Jeong IH, et al. Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis. *Mult Scler* 2016; 22: 1850–1858.
11. Kim SH, Park EY, Park B, et al. Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. *Sci Rep* 2017; 7: 9180.
12. Cho EB, Han CE, Seo SW, et al. White matter network disruption and cognitive dysfunction in neuromyelitis optica spectrum disorder. *Front Neurol* 2018; 9: 1104.
13. Oertel FC, Schließeit J, Brandt AU, et al. Cognitive impairment in neuromyelitis optica spectrum disorders: A review of clinical and neuroradiological features. *Front Neurol* 2019; 10: 608.
14. Chavarro VS, Bellmann-Strobl J, Zimmermann HG, et al. Visual system damage and network maladaptation are associated with cognitive performance in neuromyelitis optica spectrum disorders. *Mult Scler Relat Disord* 2020; 45: 102406.
15. Moore P, Methley A, Pollard C, et al. Cognitive and psychiatric comorbidities in neuromyelitis optica. *J Neurol Sci* 2016; 360: 4–9.
16. Zhang N, Li YJ, Fu Y, et al. Cognitive impairment in Chinese neuromyelitis optica. *Mult Scler* 2015; 21: 1839–1846.
17. Hollinger KR, Franke C, Arenivas A, et al. Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder. *J Neurol Sci* 2016; 362: 85–90.
18. Czarnecka D, Oset M, Karlińska I, et al. Cognitive impairment in NMOSD—More questions than answers. *Brain Behav* 2020; 10: e01842.
19. Eizaguirre MB, Alonso R, Vanotti S, et al. Cognitive impairment in neuromyelitis optica spectrum disorders: What do we know. *Mult Scler Relat Disord* 2017; 18: 225–229.
20. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. *J Neuroinflammation* 2018; 15: 134.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* 1983; 33: 1444–1452.
22. Hautzinger M, Keller F and Kühner C. *The Beck Depression Inventory II: German edition and manual of the BDI II*. Sweden: Harcourt Test Service GmbH, 2006. (In German)
23. Penner IK, Raselli C, Stöcklin M, et al. The Fatigue Scale for Motor and Cognitive Functions (FSMC): Validation of a new instrument to assess multiple sclerosis-related fatigue. *Mult Scler* 2009; 15(12): 1509–1517.
24. Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. *Neurol Neuroimmunol Neuroinflamm* 2020; 7: e674.
25. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. *J Neurol Sci* 2010; 291: 52–56.
26. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. *Brain* 1999; 122: 871–882.
27. Smith A. *Symbol digit modalities test*. Torrance, CA: Western Psychological Services, 1973.
28. Calabrese P, Kalbe E and Kessler J. A neuropsychological screening to measure cognitive dysfunction of MS patients: The multiple sclerosis inventory cognition (MUSIC). *Psychoneuro* 2004; 30: 384–388. (In German)
29. Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). *Arch Clin Neuropsychol* 2006; 21: 53–76.

30. Scherer P, Baum K, Bauer H, et al. Standardization of the brief repeatable battery of neuropsychological tests (BRB-N) in German-speaking countries. *Nervenarzt* 2004; 75: 984–990. (In German)
31. Costa SL, Genova HM, DeLuca J, et al. Information processing speed in multiple sclerosis: Past, present, and future. *Mult Scler* 2017; 23: 772–789.
32. Bruce JM, Bruce AS and Arnett PA. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. *J Int Neuropsychol Soc* 2007; 13: 544–548.
33. Guo Y, Lennon VA, Parisi JE, et al. Spectrum of sublytic astrocytopathy in neuromyelitis optica. *Brain* 2021; 145: 1379–1390.
34. Johnen A, Bürkner PC, Landmeyer NC, et al. Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). *J Neurol* 2019; 266(2): 386–397.
35. Benedict RH, Smerbeck A, Parikh R, et al. Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: Implications for multiple sclerosis clinical trials. *Mult Scler* 2012; 18(9): 1320–1325.

Visit SAGE journals online  
[journals.sagepub.com/  
home/msj](https://journals.sagepub.com/home/msj)

 SAGE journals